By:
On:
In: 9.5% stake, due diligence, fema, Finance, hemal mehta, med therapy, medtherapy biotechnology, overseas investment, sachin mehta, sebi lodr, sudarshan pharma

New Delhi [India], September 15: Sudarshan Pharma Industries Ltd has provided an update on its proposed acquisition of a 9.5% equity stake in US-based Med Therapy Biotechnology Inc., stating that the transaction is currently under due diligence. In a regulatory filing dated September 15, the company said the proposal toContinue Reading